Food Allergies and Anaphylaxis: Pathophysiology, Pharmacology, and Clinical Management

Imagine a 6‑year‑old boy named Alex who, after accidentally eating a peanut‑laden cookie, develops hives, throat swelling, and a sudden drop in blood pressure. His parents rush him to the emergency department, where a rapid epinephrine injection restores his airway and circulation. This scenario is not uncommon; food allergies affect 8–10% of children and 4% of adults worldwide, and anaphylaxis is a life‑threatening emergency that can arise within minutes of exposure. Understanding the pharmacology of the drugs that treat anaphylaxis is essential for pharmacy and medical students who will care for these patients.

Introduction and Background

Food allergies are IgE‑mediated hypersensitivity reactions that occur when the immune system mistakenly identifies a harmless dietary protein as a threat. The first documented case dates back to 1885, but it was not until the 20th century that the role of IgE and mast cells in allergic reactions was elucidated. Today, the prevalence of food allergies has risen dramatically, with peanuts, tree nuts, milk, eggs, fish, shellfish, wheat, and soy being the most common triggers. Epidemiological studies report that 1–2% of adults and up to 8% of children have clinically significant food allergies, and anaphylaxis incidence is estimated at 1–2 cases per 100,000 population per year, rising in pediatric cohorts. Anaphylaxis is a systemic, life‑threatening reaction characterized by sudden onset of hypotension, bronchospasm, urticaria, angioedema, and cardiovascular collapse. The pathophysiology involves mast cell and basophil degranulation, release of histamine, leukotrienes, prostaglandins, and platelet‑activating factor, and subsequent widespread vasodilation, increased vascular permeability, bronchoconstriction, and myocardial depression. The rapidity of onset demands prompt recognition and treatment, typically with intramuscular epinephrine, followed by adjunctive antihistamines and corticosteroids.

Mechanism of Action

Epinephrine (Adrenaline)

Epinephrine is a non‑selective adrenergic agonist that stimulates both α1‑, β1‑, and β2‑adrenergic receptors. Binding to α1 receptors causes vasoconstriction of arterioles, thereby increasing systemic vascular resistance and raising blood pressure. β1 activation enhances cardiac contractility and heart rate, counteracting the bradycardia that can accompany anaphylaxis. β2 stimulation leads to bronchodilation, relaxation of smooth muscle in the airways, and inhibition of mast cell degranulation, reducing mediator release. These combined actions rapidly reverse hypotension, bronchospasm, and airway edema, making epinephrine the first‑line therapy for anaphylaxis.

H1 Antihistamines (e.g., Diphenhydramine, Cetirizine)

H1 antihistamines block the histamine H1 receptor, preventing histamine from binding to vascular smooth muscle and epithelial cells. This inhibits vasodilation, vascular permeability, and smooth muscle contraction, thereby reducing hives, itching, and bronchoconstriction. First‑generation agents such as diphenhydramine cross the blood‑brain barrier and cause sedation and anticholinergic effects, whereas second‑generation agents like cetirizine have reduced central nervous system penetration and a more favorable side‑effect profile.

Corticosteroids (e.g., Hydrocortisone, Prednisone)

Corticosteroids exert their anti‑inflammatory effects by diffusing across cell membranes and binding to cytoplasmic glucocorticoid receptors. The hormone–receptor complex translocates to the nucleus, modulating gene transcription: it upregulates anti‑inflammatory proteins (e.g., lipocortin‑1) and downregulates pro‑inflammatory cytokines (e.g., IL‑4, IL‑5). This results in decreased eosinophil recruitment, reduced mast cell mediator release, and stabilization of endothelial barriers, thereby attenuating late‑phase allergic responses. Although steroids do not act rapidly, they are essential for preventing biphasic reactions and prolonged inflammation.

Other Adjuncts (e.g., Montelukast, Epinephrine Auto‑Injectors)

Leukotriene receptor antagonists inhibit the leukotriene D4 pathway, reducing bronchoconstriction and vascular permeability. Epinephrine auto‑injectors provide pre‑filled, ready‑to‑use doses of epinephrine, ensuring rapid administration in emergency settings. These devices are especially valuable for patients with known severe allergies who may experience delayed medical care.

Clinical Pharmacology

Pharmacokinetics

The pharmacokinetic profile of epinephrine is characterized by rapid absorption when administered intramuscularly, with peak plasma concentrations reached within 5–10 minutes. The drug has a short half‑life (~2–3 minutes) due to extensive catecholamine metabolism by catechol-O‑methyltransferase (COMT) and monoamine oxidase (MAO). Consequently, a single intramuscular dose may be insufficient in severe cases, necessitating repeat dosing every 5–15 minutes until symptoms resolve. Diphenhydramine, a first‑generation antihistamine, exhibits a bioavailability of ~70% after oral administration, with peak plasma levels at 1–2 hours. It has a half‑life of 3–5 hours and is metabolized primarily by CYP2D6. Cetirizine, a second‑generation agent, has a bioavailability of ~64%, peak levels at 1–2 hours, and a half‑life of 8–12 hours. Hydrocortisone has a half‑life of 3–4 hours when administered intravenously and is metabolized by hepatic enzymes.

Pharmacodynamics

Epinephrine demonstrates a steep dose‑response curve; therapeutic efficacy is observed at 0.01 mg/kg intramuscularly, with diminishing returns beyond 0.1 mg/kg. Diphenhydramine’s antihistaminic effect is dose‑dependent, with 10 mg providing adequate relief for mild urticaria, while 20 mg may be required for moderate cases. Cetirizine achieves maximal H1 blockade at 10 mg once daily. Hydrocortisone’s anti‑inflammatory potency is measured in terms of relative glucocorticoid activity, with 100 mg intravenous hydrocortisone approximating 5 mg of prednisone.

PK/PD Comparison Table

Therapeutic Applications

• Epinephrine – First‑line treatment for anaphylaxis; dose 0.01 mg/kg IM, maximum 0.5 mg per dose.

• Diphenhydramine – Adjunct for pruritus, urticaria; 10–20 mg PO/IV.

• Cetirizine – Long‑term prophylaxis for allergic rhinitis; 10 mg PO daily.

• Hydrocortisone/Prednisone – Prevention of biphasic reactions; 100 mg IV or 40 mg PO daily for 3–5 days.

• Montelukast – Adjunct for bronchospasm; 10 mg PO daily.

Off‑Label Uses

• Hydrocortisone IV for severe asthma exacerbations.

• Diphenhydramine IV for severe pruritus in burn patients.

• Montelukast as adjunct in chronic urticaria refractory to antihistamines.

Special Populations

• Pediatrics – Epinephrine dosing is weight‑based; caution with beta‑blockers due to potential for exaggerated hypotension.

• Geriatrics – Reduced renal clearance may prolong antihistamine half‑life; monitor for sedation.

• Renal/Hepatic Impairment – Hydrocortisone metabolism is hepatic; dose adjustment for severe liver disease.

• Pregnancy – Epinephrine is category B; antihistamines category C; corticosteroids category C but generally safe when benefits outweigh risks.

Adverse Effects and Safety

Common Side Effects

• Epinephrine: tachycardia (30–40%), palpitations (20–30%), anxiety (10–15%).

• Diphenhydramine: sedation (70%), dry mouth (50%), urinary retention (15%).

• Cetirizine: headache (10%), drowsiness (5%).

• Hydrocortisone: hyperglycemia (10–20%), mood changes (5–10%).

Serious/Black Box Warnings

• Epinephrine: arrhythmias, myocardial infarction, stroke.

• Diphenhydramine: severe CNS depression, respiratory depression in overdose.

• Hydrocortisone: adrenal suppression, osteoporosis with prolonged use.

Drug Interactions

Monitoring Parameters

• Vital signs (BP, HR) every 5–15 min after epinephrine.

• Respiratory status (RR, O2 sat) continuously.

• Blood glucose in diabetic patients receiving steroids.

• Signs of CNS depression with antihistamines.

Contraindications

• Epinephrine: severe cardiovascular disease (unstable angina, recent MI).

• Diphenhydramine: severe hepatic impairment, myasthenia gravis.

• Hydrocortisone: uncontrolled infections, active peptic ulcer.

Clinical Pearls for Practice

• PEARL 1: Always administer epinephrine intramuscularly in the lateral thigh; avoid intravascular routes.

• PEARL 2: For biphasic anaphylaxis, maintain antihistamines and steroids for 4–6 hours post‑resolution.

• PEARL 3: Use the mnemonic “E‑S‑O” – Epinephrine, Steroids, Oxygen – to remember the core treatment triad.

• PEARL 4: In patients on beta‑blockers, consider glucagon if epinephrine is ineffective.

• PEARL 5: Auto‑injector dosing is fixed; do not alter dose based on weight.

• PEARL 6: Hydrocortisone 100 mg IV is equivalent to 5 mg prednisone orally.

• PEARL 7: Monitor for late‑phase reactions; advise patients to seek care if symptoms recur within 24 hours.

Comparison Table

Exam‑Focused Review

Common USMLE/ NAPLEX Question Themes:

• Identifying epinephrine as the first‑line agent for anaphylaxis versus antihistamines as adjuncts.

• Recognizing the contraindication of epinephrine in patients on beta‑blockers and the need for glucagon.

• Understanding the pharmacokinetic difference between first‑generation antihistamines (sedative) and second‑generation agents.

• Differentiating the role of corticosteroids in preventing biphasic reactions versus their limited immediate effect.

• Applying the mnemonic “E‑S‑O” for core anaphylaxis management.

Key Differentiators Students Often Confuse:

• Intramuscular vs. intravenous epinephrine – IM is standard; IV is for refractory cases.

• First‑generation vs. second‑generation antihistamines – sedation profile.

• Epinephrine dose per kg vs. fixed dose – always weight‑based in pediatrics.

• Beta‑blocker interaction – unopposed alpha effect can worsen anaphylaxis.

Must‑Know Facts for NAPLEX:

• Auto‑injectors contain 0.3 mg epinephrine; do not dilute or alter dose.

• Hydrocortisone 100 mg IV is equivalent to 5 mg PO prednisone.

• First‑line therapy is epinephrine; do not wait for laboratory confirmation.

• Monitor patients for at least 4–6 hours after resolution.

Key Takeaways

1. Food allergies trigger IgE‑mediated mast cell degranulation, leading to anaphylaxis.

2. Epinephrine is the first‑line drug; administer IM in the thigh at 0.01–0.1 mg/kg.

3. Adjuncts—antihistamines and corticosteroids—mitigate symptoms and prevent biphasic reactions.

4. First‑generation antihistamines cause sedation; second‑generation agents are preferable for outpatient use.

5. Corticosteroids have delayed onset but are essential for long‑term control.

6. Beta‑blockers and MAOIs contraindicate epinephrine; consider glucagon if needed.

7. Auto‑injectors provide rapid, dose‑fixed epinephrine; do not alter dose based on weight.

8. Monitor vital signs, respiratory status, and glucose in diabetic patients post‑treatment.

9. Educate patients on avoidance, emergency action plans, and the use of auto‑injectors.

10. Apply the mnemonic “E‑S‑O” (Epinephrine, Steroids, Oxygen) for core anaphylaxis management.

Always remember: In anaphylaxis, time is tissue. Prompt epinephrine administration saves lives; adjuncts support recovery and prevent recurrence.